A Human Monoclonal Antibody Cocktail as a Novel Component of Rabies Postexposure Prophylaxis-Reference-Cited by-同舟云学术

A Human Monoclonal Antibody Cocktail as a Novel Component of Rabies Postexposure Prophylaxis

Published:2007-02-01 Issue:1 Volume:58 Page:359-368
ISSN:0066-4219
Container-title:Annual Review of Medicine
language:en
Short-container-title:Annu. Rev. Med.

Author:

de Kruif John¹,Bakker Alexander B.H.¹,Marissen Wilfred E.¹,Kramer R. Arjen¹,Throsby Mark¹,Rupprecht Charles E.²,Goudsmit Jaap¹

Affiliation:

1. Crucell Holland BV, Leiden, The Netherlands;

2. Rabies Section, Division of Viral and Rickettsial Diseases, Centers for Disease Control and Prevention, Atlanta, Georgia 30333

Abstract

The currently recommended treatment for individuals exposed to rabies virus is the combined administration of rabies vaccine and rabies immune globulin (RIG). This review sets out the criteria used to guide development of a cocktail of human monoclonal antibodies as a replacement for RIG. Using this process as a model, the general requirements for development of safe and efficacious monoclonal antibody alternatives to currently used polyclonal serum products are discussed.

Publisher

Annual Reviews

Subject

General Biochemistry, Genetics and Molecular Biology,General Medicine

Link

https://www.annualreviews.org/doi/pdf/10.1146/annurev.med.58.061705.145053

Cited by 69 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. mAb therapy controls CNS‐resident lyssavirus infection via a CD4 T cell‐dependent mechanism;EMBO Molecular Medicine;2023-09-28

2. Validation of Adapted Neutralization Assays Developed to Discriminate Anti-Rabies Virus Activity of Two Different Anti-Rabies Virus Monoclonal Antibodies Administered as a Combination;Biologics;2023-01-19

3. Lyssaviruses and Rabies Vaccines;Plotkin's Vaccines;2023

4. Production of Rabies virus-specific monoclonal antibodies and evaluation of their neutralizing potential;2022-11-25

5. Advances in the progress of monoclonal antibodies for rabies;Human Vaccines & Immunotherapeutics;2022-01-31